#kp2 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #kp2, aggregated by home.social.
-
#Effectiveness of the 2024–2025 #KP2 #COVID19 #vaccines in #USA during long-term follow-up, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-20242025-kp2-covid19.html
-
#Effectiveness of the 2024–2025 #KP2 #COVID19 #vaccines in #USA during long-term follow-up, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-20242025-kp2-covid19.html
-
#Effectiveness of the 2024–2025 #KP2 #COVID19 #vaccines in #USA during long-term follow-up, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-20242025-kp2-covid19.html
-
#Effectiveness of the 2024–2025 #KP2 #COVID19 #vaccines in #USA during long-term follow-up, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-20242025-kp2-covid19.html
-
#Effectiveness of the 2024–2025 #KP2 #COVID19 #vaccines in #USA during long-term follow-up, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-20242025-kp2-covid19.html
-
Kore Potash DRC ( #KP2 ) has released " Fundraise - Chairman's Participation " on Wed 02 Apr at 17:09 AEST #trading #ASX #management #price #Finance
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Fundraise - Chairman's Participation " on Wed 02 Apr at 17:09 AEST #trading #ASX #management #price #Finance
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Fundraise - Chairman's Participation " on Wed 02 Apr at 17:09 AEST #trading #ASX #management #price #Finance
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Kola Optimisation Study Update " on Thu 27 Feb at 19:39 AEST #Inflation #Russia #tax #government #Commodity
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Kola Optimisation Study Update " on Thu 27 Feb at 19:39 AEST #Inflation #Russia #tax #government #Commodity
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Kola Optimisation Study Update " on Thu 27 Feb at 19:39 AEST #Inflation #Russia #tax #government #Commodity
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Kola Optimisation Study Update " on Thu 27 Feb at 19:39 AEST #Inflation #Russia #tax #government #Commodity
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Confirmation of Mineral Resource for Kola Deposit " on Thu 27 Feb at 19:33 AEST #today #Russia #government #Mining #Australia
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Confirmation of Mineral Resource for Kola Deposit " on Thu 27 Feb at 19:33 AEST #today #Russia #government #Mining #Australia
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Confirmation of Mineral Resource for Kola Deposit " on Thu 27 Feb at 19:33 AEST #today #Russia #government #Mining #Australia
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Kore Potash DRC ( #KP2 ) has released " Confirmation of Mineral Resource for Kola Deposit " on Thu 27 Feb at 19:33 AEST #today #Russia #government #Mining #Australia
https://grafa.com/asset/kore-potash-ltd-drc-25813-kp2.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=kp2.asx -
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
#Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera
Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…
-
#Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera
Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…
-
#Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera
Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…
-
#Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera
Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…
-
#Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera
Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
Neuer Impfstoff #Comirnaty KP.2 trifft in Österreich ein orf.at/stories/3372... #KP2 #SARSCOV2 #Impfung
Neuer Impfstoff Comirnaty KP.2... -
Neuer Impfstoff #Comirnaty KP.2 trifft in Österreich ein
https://orf.at/stories/3372835/
#KP2 #SARSCOV2 #Impfung -
Neuer Impfstoff #Comirnaty KP.2 trifft in Österreich ein
https://orf.at/stories/3372835/
#KP2 #SARSCOV2 #Impfung -
Neuer Impfstoff #Comirnaty KP.2 trifft in Österreich ein
https://orf.at/stories/3372835/
#KP2 #SARSCOV2 #Impfung -
Neuer Impfstoff #Comirnaty KP.2 trifft in Österreich ein
https://orf.at/stories/3372835/
#KP2 #SARSCOV2 #Impfung -
Good news - Health Canada has just announced its approval of the new Moderna Covid vaccine, which targets the KP.2 variant. https://covid-vaccine.canada.ca/ #Covid19 #Covid #vaccine #Canada #HealthCanada #kp2 #Spikevax
-
Good news - Health Canada has just announced its approval of the new Moderna Covid vaccine, which targets the KP.2 variant. https://covid-vaccine.canada.ca/ #Covid19 #Covid #vaccine #Canada #HealthCanada #kp2 #Spikevax
-
Good news - Health Canada has just announced its approval of the new Moderna Covid vaccine, which targets the KP.2 variant. https://covid-vaccine.canada.ca/ #Covid19 #Covid #vaccine #Canada #HealthCanada #kp2 #Spikevax
-
Good news - Health Canada has just announced its approval of the new Moderna Covid vaccine, which targets the KP.2 variant. https://covid-vaccine.canada.ca/ #Covid19 #Covid #vaccine #Canada #HealthCanada #kp2 #Spikevax